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ABSTRACT
Introduction: Acute kidney injury (AKI) contributes to
morbidity and mortality, and its care is often
suboptimal and/or delayed. The Acute Kidney Outreach
to Reduce Deterioration and Death (AKORDD) study is
a large pilot testing provision of early specialist advice,
to improve outcomes for patients with AKI.
Methods and analysis: This before and after study
will test an Outreach service for adult patients with AKI,
identified using the national algorithm. During the
2-month before phase, AKI outcomes (30-day
mortality, need for dialysis or AKI stage deterioration)
will be observed in the intervention and control
hospitals and their respective community areas; no
interventions will be delivered. Patients will receive
good standard care. During the 5-month after phase,
the intervention will be delivered to patients with AKI in
the intervention hospital and its area. Patients with AKI
in the control hospital and its area will continue to
have good standard care only. Patients already on
dialysis and at end of life will be excluded. The
interventions will be initially delivered via a phone call,
with or without a visit to the primary clinician, aiming
at rapidly establishing the aetiology, correcting
reversible causes and conducting further appropriate
investigation. Surviving stage 3 patients will be
followed-up in an AKI clinic. We will conduct qualitative
research using focus group-based discussions with
primary and secondary care clinicians during the early
and late phases of the trial. This will help break down
potential barriers and improve care delivery.
Ethics and dissemination: Patients will be
contacted about the study allowing them to ‘opt out’.
The work of an Outreach team, guided by AKI alerts
and delivering timely advice to clinicians, may improve
outcomes. If the results suggest that benefits are
delivered by an AKI Outreach team, this study will lead
to a full cluster randomised trial.
Trial registration number: NCT02398682: Pre-
results.
BACKGROUND AND RATIONALE
Acute kidney injury (AKI) is a common con-
dition. Its prevalence in UK is estimated
to be >20% of emergency admissions.1
Worldwide incidence is about 21.6% in
adults in hospital settings, as shown in a
recent meta-analysis.2 Mortality due to AKI is
high. Recent studies show an overall mortal-
ity of >23% in the UK,3 and a similar per-
centage worldwide.2 There are recognised
deﬁciencies in the clinical care of patients
with AKI.4 The UK’s National Conﬁdential
Enquiry into Patient Outcome and Death
(NCEPOD)4 showed that 14% of fatal AKI
cases were avoidable. One large UK study
found that mortality in patients with AKI was
signiﬁcantly higher in the 55% of acute
trusts that did not have onsite renal teams.5
AKI aetiology is diverse, and it usually occurs
in the setting of other comorbidities.
However, few studies have looked into the
effect of non-renal comorbidities on
outcome. Charlson comorbidities have been
used to predict outcome in end-stage renal
disease.6–8 Our previous work examined the
role of comorbidity in AKI, demonstrating
the impact of solid and haematological
malignancies, as well as the total burden of
non-malignant comorbidities.9 Intensive care
patients with AKI and uncontrolled malig-
nancy are known to have poor outcome.10
Advances in technology show promise in
the early identiﬁcation of AKI, using elec-
tronic alerts.9 11 Theoretically, bringing the
Strengths and limitations of this study
▪ Acute Kidney Outreach to Reduce Deterioration
and Death (AKORDD) is a large pilot study and
the first controlled trial in unselected acute
kidney injury (AKI) in the UK.
▪ It employs a before and after design in control
and intervention hospitals and their areas.
▪ It uses the national AKI algorithm in hospital and
community to identify cases.
▪ The intervention is delivered by the Outreach
team for all eligible cases in working hours.
▪ With only two sites, it is not a full cluster rando-
mised study.
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recent rise in creatinine to clinicians’ attention should
prompt improvements in management. However, a
recent study using alerts alone failed to demonstrate any
improvements in outcome.12
The concept of an Outreach team has been estab-
lished in critical care for many years, offering rapid
assessment to deteriorating patients. One large cluster
randomised trial (CRT) failed to show a signiﬁcant
impact of Medical Emergency Team in reducing hospital
cardiac arrests.13 In the UK, the introduction of critical
care Outreach in an 800-bed general hospital signiﬁ-
cantly reduced mortality.14 Two large meta-analyses were
conducted analysing trials of rapid response teams
(RRTs). Outreach teams were successful in reducing
non-intensive care unit cardiac arrest by 34%, but mor-
tality was not signiﬁcantly reduced.15 Overcoming the
barriers to implementation of the RRT service would
further improve outcome.16 The dissociation between
decline of cardiac arrest rates and mortality is not fully
understood.
The use of an Outreach team for renal patients is
novel. We piloted a renal Outreach team in 2009, offer-
ing early specialist advice for patients who developed
AKI. The team delivered limited dose (3 hours a day,
5 days/week) telephone advice to clinicians looking
after patients with AKI. Two hundred and sixty-two alerts
were identiﬁed with a successful telephone call in 88%
of the cases. Considerable numbers of recommendations
were made. These included optimisation of ﬂuid status
and medication management.17 There has also been
one other, smaller pilot of early intervention in AKI.18
The adverse sequelae of an AKI episode continue
even after its complete or partial resolution. It may be
valuable to have early renal follow-up, especially for
severe cases. A retrospective study suggested that early
follow-up of patients with AKI, especially those not previ-
ously known to nephrology services, may reduce
mortality.19
The true cost of AKI is unknown as existing studies are
retrospective. Calculating the cost of AKI syndrome is
important to assess the burden to the healthcare systems.
The healthcare costs for patients with AKI have a robust
relationship to the severity of AKI.20 It was estimated in
previous studies that prevention of 30% of AKI cases
would save the National Health Service (NHS) between
£130 and £186 million per year.21 In a European study, it
was shown that conservative management of AKI, includ-
ing the initial hospitalisation and 2-year follow-up,
incurred average costs of €34 000, and this increased to
€40 000–€55 000 if a patient had dialysis (depending on
the modality).22 The ﬁnancial burden includes inpatient,
critical care and postdischarge costs (the latter encom-
pass progression of chronic kidney disease (CKD) with or
without renal replacement therapy).21
Overall, the study’s primary aim is to test the feasibility,
systems for and value of the Outreach team approach on
the measured outcomes in patients with AKI, before a
planned CRT.
METHODS
Overall study design
We will run a quasi-experimental trial of a complex multi-
factorial intervention.23 Using a before and after study
design, we will pilot the Outreach service to patients with
AKI. Patients will be recruited once they have an elec-
tronic alert indicating that they have AKI. Inclusion and
exclusion criteria will then be applied (box 1). There will
be no patient-level randomisation to avoid the risk of con-
tamination, as this is a pilot for a CRT. The study has
been approved by (1) the National Research Ethics
Service (Reference: 14/EM/0184, NRES Committee East
Midlands—Nottingham 1, approved 22 May 2014) and
(2) the Conﬁdentiality Advisory Group (CAG Reference:
CAG 2-07(a)/2014—approved 30 May 2014).
It was impractical to take written informed consent
from the large numbers of patients involved over two
hospitals, when the study was focused on providing AKI
Outreach to clinicians. Therefore, it was agreed with the
research ethics committee that we would write to all
enrolled patients giving them an ‘opportunity to dissent’
or ‘opt out’ of the study. The opt out letter will be sent
to the patient’s home address as soon as possible after
enrolment. In conjunction with the opt out letter, a
leaﬂet explaining AKI will be sent to patients in the
intervention group only.
Box 1 Inclusion and exclusion criteria for the Acute
Kidney Outreach to Reduce Deterioration and Death
(AKORDD) study
Inclusion criteria:
▸ Adult (≥18 years) patients with an alert due to AKI from a
blood test arising from Heartlands or Good Hope Hospitals
(and their associated postcodes for outpatients/primary care).
▸ AKI stage 1, 2 or 3.
Exclusion criteria:
▸ Patient deceased at the time of Outreach team intervention.
▸ Patient already accepted for dialysis by HEFT renal unit.
▸ Known dialysis/end-stage renal disease patients (excluded
from alerts).
▸ Other patients with stable chronic kidney disease (definition of
stable CKD), or progressive CKD where there is no obvious
change in the rate of progression of the CKD (ie, no acute
deterioration, just steady progression).
Patients with CKD and stage 1 AKI based on an absolute cre-
atinine rise of ≥26 µmol/L but who have a relative rise of ≤15%
in creatinine are regarded as stable CKD and therefore not eligible
for the study.
▸ Children or young people <18 years of age.
▸ Patients in the terminal phase of malignancy or end-stage
major organ disease where they have little potential to benefit
from Outreach. These would typically be identified as having a
life expectancy likely to be <3 months.
▸ Patients lacking mental capacity (unless enrolment agreed in
writing with a personal consultee or nominated consultee
(after phase) or personal consultee (before phase)).
▸ Other technical aspects of making alert not credible: inad-
equate data; suppressed creatinine at baseline.
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The study is registered at ClinicalTrials.gov
(NCT02398682). It is funded by the Research for Patient
Beneﬁt programme of the UK National Institute for
Healthcare Research (PB-PG-1111-26038) and sponsored
by the Heart of England Foundation Trust. The trial has
two phases and four groups (2 during each phase—see
also ﬁgure 1):
A. The before phase
During the 2-month before phase, patients in the two
groups will be observed for the outcome measures, with-
out any intervention, thus deﬁning outcomes with good
standard care. There will be two before phase groups:
1. Heartlands and area patients—patients with AKI in
secondary and primary care—observed only.
2. Good Hope and area patients—patients with AKI
in secondary and primary care—observed only.
B. The after phase
During the 5-month after phase, the intervention will be
delivered to the intervention group (Heartlands and
area) only. There will be two after phase groups:
1. Heartlands hospital and area patients—interven-
tion provided for patients with AKI in secondary
and primary care, mainly using Outreach via tele-
phone (see below).
2. Good Hope hospital and area patients—patients
with AKI in secondary and primary care—observed
only.
Data collection and recruitment
Data collection will be carried out using a Concerto clin-
ical portal (V.8.3) and database (Orion Health, London,
UK), embedded within the Trust’s IT system. All AKI
alerts (discussed below) are visible to the study team in
a list in Concerto. Patients not previously enrolled in the
study can be virtually ‘transferred’ into the study data-
base at enrolment.
A key point is that each patient can only be recruited
once to the study, and thus a given patient cannot be
recruited to the before phase, and then later to the after
phase. This avoids the ethical issue of double recruit-
ment. Thus, a patient enrolled during the before phase
cannot be enrolled in the after phase, if they have a
further episode of AKI. The recruitment of more ‘recur-
rent’ patients with AKI during the 8-week before phase
presents a potential limitation, but in our view, it is
balanced by the much longer 20-week after phase.
Patients enrolled in the intervention (Heartlands after
phase) group remain a ‘customer’ in the care of the
AKI Outreach team if they have a recurrent episode of
AKI, and their clinician(s) can receive further Outreach
intervention(s) as required. In practice, we believe that
this is the way any AKI Outreach team will work in
future. The study recruitment will run from mid-2015 to
later in 2016.
Core study methodology
To allow replication of the model throughout the wider
NHS, we provide the updated TIDieR checklist (see
online supplementary ﬁles).24
Alerts
The electronic AKI alerts are the trigger for the afferent
arm of the intervention. The alerts are generated within
the laboratory software (Telepath, Computer Sciences
Corporation) according to the national algorithm.25 It
Figure 1 Study flow chart.
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compares the current patient creatinine to a value in the
past (baseline creatinine). The staging follows KDIGO
guidelines for AKI,26 where 0 is no AKI and 3 is the
most severe stage. Alerts are made visible to all users of
the electronic patient records, with the stage being
stated as part of all urea, creatinine and electrolyte
reports. The alerts from our hospital laboratory also
contain a hyperlink to online guidance, with separate
guidance for hospital and community alerts. Alerts are
not issued for patients in the dialysis units and renal
wards. We refer to the current location of the patient
when discussing community (primary care) or hospital
alerts. Obviously some of the hospital alerts will repre-
sent what was community-acquired AKI, but Outreach
focuses on the current location of the patient.
Hospital sites
The Heart of England Foundation Trust consists of
three hospitals. Good Hope Hospital was selected as
control site as it is larger and relatively similar to the
intervention site of Heartlands Hospital in its services.
For a detailed description of both hospitals, please refer
to online supplementary ﬁle 1.
Primary care sites
A large proportion of all AKI cases begin in the commu-
nity. We, therefore, felt that it was important to include
patients with AKI in the community in the study, as this
provides the earliest opportunity to intervene in the care
of the patient. Primary care clinicians see AKI alerts in
the patients’ electronic laboratory reports (implemented
after consultation as part of the start of the study—about
9 months ahead of the national schedule). We have
mapped >17 000 emergency admissions presenting to
the three hospitals during a calendar month to identify
which areas predominantly present to Heartlands hos-
pital, and similarly to Good Hope hospital. We are,
therefore, able to allocate any patient with AKI in the
community in these postcodes to either the control
(postcode areas B23, B24, B35, B43, B44 and B72–B79)
or the intervention arms (postcode areas B7–B11, B25,
B26, B33, B34, B36, B37, B40 and B46). A small number
of general practices in our area do not use the hospital
laboratories of the Trust, and therefore, any alerts for
their patients were not available to the study team.
After phase sample size
For the before phase, no sample size is required and eli-
gible patients during the study period will be recruited.
The sample size was calculated with the intent of esti-
mating uncertainty of outcomes, to inform the design of
the future cluster trial. Our previous work suggested that
the combined outcome would be seen in about 40% of
patients having an alert. With a sample size of >1000
(intervention group—Heartlands and area, after phase),
a 95% CI of width 6% (37% to 43%) can be calculated.
A sample size of 370 (control group—Good Hope and
area, after phase) will allow us to produce a 95% CI of
width 10% (35% to 45%).
Study team
The AKI Outreach team will function during working
hours, 5 days/week. The ideal service, addressing AKI
7 days a week, is beyond the resources of this pilot. The
model is a mixed skills team, allocating tasks using an
electronic list of alerts and the electronic study database.
The core Outreach team consists of an experienced
renal consultant (usually the Chief Investigator), renal
research fellow (working at junior specialist registrar
level) and a critical care research (trained in AKI care)
nurse. The core clinical team members will be primarily
responsible for delivering the interventions, in the form
of telephone consultation, with or without a ward visit,
triggered by the AKI alert. The core team members are
supported by other research staff, who help with the
research data collection. Each working day patients are
prioritised according to AKI severity.
Data collected
In the study database, we will collect data on the causes
of AKI and the associated comorbidities for all patients,
as well as medication used at the time of AKI. Causes
will be determined in pragmatic fashion from the elec-
tronic records, including prerenal/renal hypoperfusion,
nephrotoxic medications, intrinsic or specialist renal dis-
eases (not covered elsewhere), urological/postrenal and
surgical causes. We will determine comorbidities accord-
ing to a modiﬁed Charlson scheme as previously
reported,9 and in addition stage solid neoplasia using
the Surveillance, Epidemiology, and End Results staging
system.27 28
Interventions
In majority of cases, interventions will be in the form of
phone call to the clinical team looking after the patient.
The phone call will be structured to obtain verbal
consent of the clinician at the start of the call. The dur-
ation of the call will be tailored according to clinical
complexity and expected outcome of the case. All inter-
ventions will be recorded on the trial database in order
to measure ‘dose’. In view of the large numbers
managed by a small Outreach team, we anticipate that
most interventions will rely on a single call, with no
follow-up. Key feasibility measures in the intervention
phase will be the time from alert to intervention, and
the median number of recommendations (in compari-
son to our previous work17).
Intervention package
The Outreach team will advise on an evidence-based
package of care (these interventions are limited to the
intervention arm):
1. Diagnostic and monitoring recommendations—to rapidly
establish a credible diagnosis of the cause of AKI
including:
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A. Improved assessment of volume status;
B. Standardised use of urine dipstick (often missed);
C. Appropriate sepsis investigations;
D. Urgent ultrasound with suspected obstruction,
while avoiding early ultrasound in patients at low
risk of obstruction.
2. AKI treatment recommendations—to treat correctable
causes of AKI:
A. Rapid, limited treatment of hypovolaemia, with
avoidance of iatrogenic ﬂuid overload, recently
recognised as a signiﬁcant cause of mortality in
AKI;
B. Rapid sepsis therapy;
C. Cessation of potentially nephrotoxic agents (many
well known, such as ACE inhibitors and non-
steroidal drugs, but others less well known such as
Aciclovir);
D. Urgent relief of urinary tract obstruction.
3. Recommendations to manage the acute illness:
A. Where needed, recommendations will be made to
address key aspects of the major underlying
comorbidity;
B. Improve nutrition, as malnutrition is known to be
associated with poor outcome. Dietetic referral
will be made for all appropriate inpatients with
stage 3 AKI.
4. Pathway recommendations:
A. For inpatients, refer to the Renal and/or Critical
Care Outreach teams, as appropriate;
B. For patients in the community, arrange urgent or
immediate outpatient review or admission, as
appropriate;
C. Arrange formal palliative care when necessary.
5. Stage-based AKI management:
A. Stage 1 patients will typically receive a single inter-
vention call;
B. Stage 2 patients will usually receive a single inter-
vention call and be discussed with the renal
consultant;
C. Stage 3 inpatients will be reviewed by a consult-
ant, ideally within 24 hours of the AKI Outreach
team being aware of their presence in the inter-
vention hospital (Heartlands Hospital);
D. Rapid AKI follow-up clinic—we will offer surviving
patients with stage 3 AKI a rapid follow-up clinic
appointment, ideally within 7 days of discharge,
or within 7 days of the alert if the patient is not
admitted to hospital.
The health economics substudy
We will pilot a prospective health economic assessment,
calculating the cost of AKI. We aim to deﬁne with more
accuracy the true total cost of an AKI episode. We will
also pilot assessment of the costs of the Outreach service
and its recommendations, using national tariffs for the
latter. The information will be extracted from the elec-
tronic patient records or the paper records. The costs of
long-term sequelae such as dialysis will be included. For
the purpose of the pilot health economics substudy, we
will obtain a sample of 50 patients, divided into 25
patients from the intervention group and 25 from the
control group. We will open ‘recruitment weeks’ to run
simultaneously at both sites until the numbers are met
at each site. We will break down the service components
(including, eg, the time of the phone call), any labora-
tory or radiological tests, and we will use the NHS cost
codes. We will use the EQ-5D-5L questionnaire,29 which
is a standardised short quality-of-life questionnaire,
which has been used in various populations, including
critically ill patients with AKI,30 since its development in
1990.31 We will record the ﬁve dimensions of health
status and the visual analogue scale results,32 at the time
of AKI (0 months). The EQ-5D-5L, and in addition a
health resource use questionnaire (based on those from
DIRUM (Database of Instruments for Resource Use
Measurement)),33 will be completed by telephone at 3,
6, 9 and 12 months.
Fidelity
We will pilot a ﬁdelity assessment, examining interven-
tion adherence, in conjunction with the health eco-
nomic analysis, using the 25 patients recruited to the
above analysis at the intervention site. In the ﬁdelity and
health economic work, each patient record will be exam-
ined in detail to extract the adherence to recommenda-
tions as well as all the costs of the admission.
Quantitative analysis of clinical data
Estimates for the CRT
The main aim of this study is to test feasibility of the inter-
vention and all study procedures. In addition, this pilot
study will allow estimates of the uncertainty of the primary
outcome (deterioration or death) to be used in planning
a cluster trial. Secondarily, data from this study can be
used to assess the prognostic model previously intro-
duced. In addition, simple analyses will be conducted to
look at CKD progression or development of end-stage
renal disease as a result of AKI episode, and survival to dis-
charge to a more dependent setting than at admission.
Outcomes
The primary purpose of this study is to assess feasibility
and inform a full cluster randomised study. The primary
outcome for the full study, also collected in this study, is
reﬂected in the trial acronym: deterioration or death of
the patient with AKI, and is a combination of:
A. All-cause death within 30 days;
B. Any need for dialysis or renal replacement ther-
apy (intermittent haemodialysis (typically at the
Renal Unit of Birmingham Heartlands Hospital) or
continuous renal replacement therapy (typically in
the intensive care units of the Trust)) within 30 days;
C. Progression of AKI stage without dialysis within
30 days after the alert (stage progression is stage 1
deteriorating to 2 or 3; stage 2 deteriorating to
stage 3).
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These were chosen to reﬂect the major, potentially
modiﬁable, outcomes of concern for patients (death
and/or dialysis) and renal units or hospitals (death, dia-
lysis or deterioration). Stage progression (compared to
non-progression) is known to be associated with
increased mortality and length of stay in a multivariate
analysis,34 and is a useful surrogate end point.
Secondary outcomes for the main study, collected to
assess feasibility here, are as follows:
Measured outcome Time window
Percentage of patients admitted
to hospital
Within 14 days of alert
Percentage requiring any critical
care admission
During index admission
Other key events (see below) During index admission
Percentage discharged to
institutional care
After index admission
All-cause mortality At 90, 182 and 365 days
Renal function (eGFR) At 90, 182 and 365 days
In a pragmatic study, patients will not be recalled for
renal function testing; at the time points above, we will
use the last observation carried forward for all living
patients. Key events are these events as given in the dis-
charge letter:
1. Cause of AKI: new glomerulonephritis or new
urinary obstruction diagnosis.
2. Complication of AKI not requiring dialysis: new pul-
monary oedema, uraemia ≥30 mmol/L or hyperka-
laemia (≥6.0 mmol/L).
Statistical analysis
The focus of the study is to assess feasibility of all aspects
prior to full-scale evaluation. The data collected in this
pilot study will be used to assess the uncertainty of the
primary outcome. Further analyses will separately
compare the before and after arms at the intervention
and control sites. We note that the intervention and
control sites cannot be directly compared. The control
site data will be used to assess any ‘system-wide’ change in
AKI outcomes. Additionally, survival analyses will be
carried out, examining time to ﬁrst composite primary
outcome, and Kaplan-Meier survival curves produced for
each of the four groups. This pilot study is not powered
to provide a full comparison of the before and after
phases. Among the end points, the use of dialysis and fre-
quency of non-dialytic AKI complications will give an
indication of the safety of the intervention. We will
analyse estimated Glomerular Filtration Rate (eGFR) and
CKD stage at a group level and changes at individual
patient level. We will also explore the potential of using
these data to validate our previous prognostic index.9
Qualitative work
Prestudy
A challenging area of development is the communica-
tion with primary care and secondary care clinicians. We
carried out prestudy qualitative research on the poten-
tial role of an AKI Outreach team. The aim of the focus
groups was to explore the barriers that might hinder the
application of optimum care for patients with AKI. We
conducted eight focus groups with the primary clinicians
and hospital doctors to explore their experience with
AKI management, and the best methods to enhance
this. Our qualitative work will be separately presented.
Poststudy
The poststudy qualitative work will use focus groups and
interviews to examine the experience of clinicians
receiving AKI Outreach advice during the intervention
phase, aided by the voice recording of the Outreach
call. We will use purposeful sampling to explore a spread
of possible perspectives, for example, doctor role/senior-
ity, different reasons for AKI and different AKI stages.
We will carry out a realistic evaluation of the role of
Outreach, using one-to-one interviews for general practi-
tioners and focus groups for four hospital specialties
(critical care; acute medicine; elderly care and surgical
specialties). The recordings for those clinicians will be
evaluated using a realistic evaluation,35 to explore ‘what
works, for whom and in what circumstances’.
Discussion and limitations of the study
The national algorithm for staging of AKI means that
identiﬁcation of patients with AKI is standardised. The
‘opt out’ consent process enables large-scale recruit-
ment. The ethos of AKI Outreach is that advice is
offered to the primary clinician, who may choose to act
upon or ignore that advice. A key challenge in imple-
menting the intervention is reaching and inﬂuencing
the decision maker(s) within the primary team, espe-
cially as they have varying roles and beliefs.
The AKI Outreach service runs only 40 hours/week
and not out-of-hours. As this is a pilot for a full CRT,
there were only two sites and randomisation was not
undertaken. Inevitably, the intervention and the control
sites are different to a certain extent. The latter does not
have on-site nephrology services. A full CRT is needed to
provide a deﬁnitive answer regarding any beneﬁts of this
approach. What would a successful pilot look like? The
delivery of recommendations acceptable to clinicians,
comparable to our previous work (median of 3 within a
median of 15 hours), and to large numbers of patients is
a key indicator of success. The control group should show
no evidence of a system-wide change in before and after
AKI outcomes. The intervention group will provide evi-
dence of the feasibility and safety of the intervention.
Conclusions
The Acute Kidney Outreach to Reduce Deterioration
and Death (AKORDD) is a pilot study of an acute kidney
Outreach team, and is needed to lay the foundations for
use of this novel intervention in developed healthcare
systems. It potentially provides a way of improving out-
comes in the syndrome that is AKI. If it shows that AKI
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Outreach is feasible and safe, then it will act as an import-
ant ‘pathﬁnder’ study for a large, multicentre, CRT.
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